Review of antifungal therapy and the severity index for assessing onychomycosis: Part I

Journal of Dermatological Treatment

Volumn 19, Issue 2, 2008, Pages 72-81

  Baran, Robert ^a   Hay, Rod J ^b,d   Garduno, Javier I ^c  

^a NAIL DISEASE CENTRE   (France)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d International Foundation of Dermatology   (United Kingdom)

Author keywords

Adverse reactions; Antifungal; Onychomycosis; Severity index

Indexed keywords

[4 (2,4 DICHLOROPHENYL) 1,3 DITHIOLAN 2 YLIDENE](1 IMIDAZOLYL)ACETONITRILE; AMOROLFINE; ANTACID AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; BUTENAFINE; CICLOPIROX; EBERCONAZOLE; EUGENOL; FLUCONAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; INDINAVIR; ISONIAZID; ITRACONAZOLE; LANOCONAZOLE; MICAFUNGIN; NEVIRAPINE; POSACONAZOLE; PROTON PUMP INHIBITOR; R 1266638; RAVUCONAZOLE; RIFABUTIN; RIFAMPICIN; RILOPIROX; SERTACONAZOLE; SILDENAFIL; TERBINAFINE; UNINDEXED DRUG; VORICONAZOLE; WARFARIN;

ABDOMINAL PAIN; ADRENAL INSUFFICIENCY; AGRANULOCYTOSIS; ANGIONEUROTIC EDEMA; ARTHRALGIA; BURNING SENSATION; CONGENITAL MALFORMATION; CONTACT DERMATITIS; COST EFFECTIVENESS ANALYSIS; DEBRIDEMENT; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG METABOLISM; DRUG TISSUE LEVEL; DYSPEPSIA; ECZEMA; ERYTHEMA; ERYTHRODERMA; FLATULENCE; FUNGICIDAL ACTIVITY; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS; HUMAN; HYPOKALEMIA; LEUKOPENIA; LIVER FUNCTION; LONG TERM CARE; MONOTHERAPY; MYALGIA; NAUSEA; NEUTROPENIA; ONYCHOLYSIS; ONYCHOMYCOSIS; PRIORITY JOURNAL; PUSTULOSIS; RASH; REVIEW; SEIZURE; SIDE EFFECT; SKIN DISCOLORATION; SKIN EDEMA; SKIN IRRITATION; STEVENS JOHNSON SYNDROME; SURGICAL NAIL AVULSION; SURGICAL TECHNIQUE; TASTE DISORDER; THROMBOCYTOPENIA; TINEA PEDIS; TOXIC EPIDERMAL NECROLYSIS; URTICARIA; VOMITING;

ANTIFUNGAL AGENTS; HUMANS; ONYCHOMYCOSIS; SEVERITY OF ILLNESS INDEX;

EID: 45949095795     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630701243418     Document Type: Review

References (69)

1. Marty JPL. Amorolfine nail lacquer: A novel formulation. J Eur Acad Dermatol Venereol. 1995;4 Suppl 1: S17-S22.
2. Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol. 2000;43:S70-S80.
3. Effendy I. Therapeutic strategies in onychomycosis. J Eur Acad Dermatol Venereol. 1995;4 Suppl 1: S3-S10.
4. Gupta AK, Joseph WS. Ciclopirox 8% nail lacquer in the treatment of onychomycosis of toenails in the United States. J Am Podiatr Med Assoc. 2000;90:495-501.
5. Seebacher C, Ulbricht H, Wörz K. Results of a multicentre study with ciclopirox nail lacquer in patients with onychomycosis. Hautnah Myk. 1993;3:80-4.
6. Nolting S, Ulbricht H. Untersuchungen zur Applikationsfrequenz von Ciclopirox-lack (8%) bei der Behandlung von Onychomycosen. Jatrox Derma. 1997;11:20-6.
7. Polak A, Jäckel A, Noack A, Kappe R. Agar sublimation test for the in vitro determination of the antifungal activity of morpholine derivatives. Mycoses. 2004;47:184-92.
8. Flagothier C, Piérard-Franchimont C, Piérard GE. New insights into the effect of amorolfine nail lacquer. Mycoses. 2005;48:91-4.
9. Rigopoulos D, Katsambas A, Antoniou C, Christofidou E, Balaskas E, Stratigos J. Discoloration of the nail plate due to the misuse of amorolfine 5% nail lacquer. Acta Derm Venereol. 1996;76:83-4.
10. Kim BJ, Ro BI. Hyperpigmentation due to the overuse of amorolfine nail lacquer. Korean J Med Mycol. 2002;7:224-6.
11. Lee JH, Roh KY, Park HJ, Lee JY, Cho BK. Painful nail due to the use of amorolfine nail lacquer. Third Korea-China International Conference of Dermatology and Mycology, Seoul, Korea, May 31 to June 1, 2001: Poster 51.
12. Baran R, de Donker P. Lateral edge nail involvement indicates poor prognosis for treating onychomycosis with the new systemic antifungals. Acta Derm Venereol. 1996;76:82-3.
13. Hay RJ. Chronic dermatophyte infections. In: Verbov J, editor. Superficial fungal infections. Lancaster, UK: MTP Press; 1986. p. 23-4.
14. Roberts DT, Evans EGV. Subungual dermatophytoma complicating dermatophyte onychomycosis. Br J Dermatol. 1998;138:189-90.
15. Baran R, Tosti A, Piraccini BM. Uncommon clinical patterns of Fusarium nail infection: Report of three cases. Br J Dermatol. 1997;136:424-7.
16. Rollman O, Johansson S. Hendersonula toruloidea infection: Successful response of onychomycosis to nail avulsion and topical ciclopiroxolamine. Acta Derm Venereol. 1987;67:506-10.
17. Dominguez-Cherit J, Teixeira F, Arenas R. Combined surgical and systemic treatment of onychomycosis. Br J Dermatol. 1999;140:778-80.
18. Baran R, Hay RJ. Partial surgical avulsion of the nail in onychomycosis. Clin Exp Dermatol. 1985;10:413-18.
19. Baran R, Bureau H. Surgical treatment of recalcitrant chronic paronychia of the fingers. J Dermatol Surg Oncol. 1981;7:106-7.
20. South DA, Farber EM. Urea ointment in non surgical avulsion of nail dystrophies. Reappraisal. Cutis. 1980;26:609-12.
21. Buselmeier T. Combination urea and salicylic acid ointment nail avulsion in non dystrophic nails: Follow-up observation. Cutis. 1980;25:397-405.
22. Dorn M, Kienitz T, Ryckmanns F. Onychomycosis: Experience with non traumatic nail avulsion. Hautarzt. 1980;31:30-4.
23. Torres-Rodriguez JM, Madreny N, Nicolas MC. Nontraumatic topical treatment of onychomycosis with urea associated with bifonazole urea in the two-phase treatment of onychomycosis. Mycoses. 1991;34:499-504.
24. Bonifaz A, Guzman A, Garcia C, Sosa J, Saul A. Efficacy and safety of bifonazole urea in the two-phase treatment of onychomycosis. Int J Dermatol. 1995;34:500-3.
25. Baran R, Coquard F. Combination of fluconazole and urea in a nail lacquer for treating onychomycosis. J Dermatolog Treat. 2005;16:52-5.
26. Di Chiacchio N, Kadunc BV, De Almeida ART, Madeira CL. Nail abrasion. J Cosmet Dermatol. 2003;2:150-2.
27. Haneke E. The potential risks of not treating onychomycosis. In: Proceedings of the 2nd International Symposium on Onychomycosis, Florence, 1995. Macclesfield, UK: Gardiner-Caldwell Comm Ltd; 1966. p. 12-14.
28. Grant SM, Clissold SP. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs. 1989;37:310-44.
29. Haria M, Bryson HM, Goa KL. Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs. 1996;51:585-620.
30. De Doncker P, Decroix J, Piérard GE, Roelant D, Woestenborghs R, Jacqmin P, et al. Antifungal pulse therapy in onychomycosis: A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse with itraconazole. Arch Dermatol. 1996;132:34-41.
31. Nolting S. Satellite Symposium. Onychomycosis. New approaches in therapy. Proceedings of the 19th World Congress of Dermatology, Sydney, Australia, June 18 1997.
32. Fischbein A, Haneke E, Lacner K, et al. Comparative evaluation of oral fluconazole and oral ketoconazole in the treatment of fungal infections of the skin. Int J Dermatol. 1992;31 Suppl 2: 12-16.
33. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother. 1995;39:1-8.
34. Goa KL, Barradell LB. Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs. 1995;50:658-90.
35. Rich P, Scher RK, Breneman D, Savin RC, Feingold DS, Konnikov N, et al. Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail. J Am Acad Dermatol. 1998;38:S103-9.
36. Savin RC, Drake L, Babel D, Stewart DM, Rich P, Ling MR, et al. Pharmacokinetics of three once-weekly dosages of fluconazole (150, 300, or 450 mg) in distal subungual onychomycosis of the fingernail. J Am Acad Dermatol. 1998;38:S110-16.
37. Scher RK, Breneman D, Rich P, Savin RC, Feingold DS, Konnikov N, et al. Pharmacokinetics and efficacy of once-weekly fluconazole (150, 300 or 450 mg) in distal subungual onychomycosis of the toenail. J Am Acad Dermatol. 1998;38:S77-86.
38. Drake L, Babel D, Stewart D, Rich P, Ling MR, Breneman D, et al. Once-weekly fluconazole (150, 300 or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail. J Am Acad Dermatol. 1998;38:S87-S94.
39. Ling MR, Swinyer LJ, Jarratt MT, Falo L, Monroe EW, Tharp M, et al. Once-weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail. J Am Acad Dermatol. 1998;38:S95-S102.
40. Fräki JE, Heikkila HT, Kero MO, Kuokkanen KE, Oksman RO, Rantanen TT, et al. An open-label, noncomparative, multicenter evaluation of fluconazole with or without urea nail pedicure for treatment of onychomycosis. Curr Therap Res. 1997;58:481-91.
41. Ryder NS. Terbinafine: Mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol. 1992;126:2-7.
42. Balfour JA, Faulds D. Terbinafine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs. 1992;43:259-84.
43. Faergemann J, Zehender H, Millerioux L. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days. Clin Exp Dermatol. 1994;19:121-6.
44. Hall M, Monka C, Krupp P, O'Sullivan D. Safety of oral terbinafine: Results of a post-marketing surveillance study in 25.884 patients. Arch Dermatol. 1997;133:1213-19.
45. Garcia Rodriguez LA, Duque A, Castellsague J, Perez-Gutthann S, Stricker BH. A cohort study of the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol. 1999;48:847-52.
46. Stricker BH, van Riemsdijk MM, Sturkenboom MC, Ottervanger JP. Taste loss to terbinafine: A case-control study of potential risk factors. Br J Clin Pharmacol. 1996;42:313-18.
47. Vantaux P, Grasset D, Nougue J, Lagier E, Seigneuric C. Hépatite aiguë en rapport avec la prise de terbinafine. Gastroenterol Clin Biol. 1996;20:402-3.
48. Rzany B, Mockenhaupt M, Gehring W, Schöpf E. Stevens-Johnson syndrome after terbinafine therapy. J Am Acad Dermatol. 1994;30:509.
49. Carstens J, Wendelboe P, Sogaard H, Thestrup-Pedersen K. Toxic epidermal necrolysis and erythema multiforme following therapy with terbinafine. Acta Dermatol Venereol. 1994;74:391-2.
50. Jenssen JC. Pharmacokinetics of lamisil in humans. J Dermatol Treat. 1990; Suppl 2: 15-18.
51. Svejgaard EL, Brandrup F, Kragballe K, Larsen PO, Veien NK, Holst M, et al. Oral terbinafine in toenail dermatophytosis. A double-blind, placebo-controlled multicenter study with 12 months' follow-up. Acta Dermatol Venereol. 1997;77:66-9.
52. Sigurgeirsson B, Olafsson JH, Steinsson JB, Paul C, Billstein S, Evans EG. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: A 5-year blinded prospective follow-up study. Arch Dermatol. 2002;138:353-7.
53. Cribier BJ, Bakshi R. Terbinafine in the treatment of onychomycosis: A review of its efficacy in high-risk populations in patients with nondermatophyte infections. Br J Dermatol. 2004;150:414-20.
54. Segal R, Kritzman A, Cividalli L, Samra Z, David M, Tiqva P. Treatment of Candida nail infection with terbinafine. J Am Acad Dermatol. 1996;35:958-61.
55. Nolting S, Brautigam M, Weidinger G. Terbinafine in onychomycosis with involvement by non-dermatophytic fungi. Br J Dermatol. 1994;130 Suppl 43: 16-21.
56. Zaidi Z, Jafri N, Khan K, Hasan P, Kapadia N. Open label trial of the efficacy and tolerability of Lamisil (terbinafine) 500 mg once daily in the treatment of onychomycosis due to candida. J Pak Med Assoc. 1996;46:258-60.
57. Goodfield MJD, Evans EGV. Combined treatment with surgery and short duration oral antifungal therapy in patients with limited dermatophyte toenail infection. J Dermatolog Treat. 2000;11:259-62.
58. Goodfield MJD, Bosanquet N, Evans EGV, Winther-Pedersen AL, Perrin VL. Cost effective clinical management of onychomycosis. Br J Med Econ. 1994;7:15-23.
59. Baran R, Kaoukhov A. Topical antifungal drugs for the treatment of onychomycosisi: An overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venereol. 2005;19:21-9.
60. Pierard GE, Pierard-Franchimont C, Arrese JE. The boosted oral antifungal treatment for onychomycosis beyond the regular itraconazole pulse dosing regimen. Dermatology. 2000;200:185-7.
61. Goffin V, Arrese JE, Pierard GE. Onychomycoses récalcitrantes et le 'low-coast BOAT' au fluconazole. Skin. 2002;5:145-7.
62. Pierard GE, Pierard-Franchimont C, Arrese JE. The boosted antifungal topical treatment (BATT) for onychomycosis. Med Mycol. 2000;38:391-2.
63. Gupta AK, Leonardi C, Stoltz RR, Pierce PF, Conetta B. Ravuconazole onychomycosis group. A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. J Eur Acad Dermatol Venereol. 2005;19:437-43.
64. Mamta P, Sushil S. Utilization of pericarp of Citrus sinensis oil for the development of natural antifungal against nail infection. Curr Sci. 2003;84:1512-15.
65. Gayoso CW, Lima EO, Oliveira VT, Pereira FO, Souza EL, Lima IO, et al. Sensitivity of fungi isolated from onychomycosis to Eugenia cariophyllata essential oil and eugenol. Fitoterapia. 2005;76:247-9.
66. Baran R, Coquard F. Combination of fluconazole and urea in a nail lacquer for treating onychomycosis. J Dermatolog. Treat. 2005;16:52-5.
67. Kamp H, Tietz HJ, Lutz M, Piazena H, Sowyrda P, Lademann J, et al. Antifungal effects of 5-aminolevulinic acid PDT in Trichophyton rubrum. Mycoses. 2005;48:101-7.
68. Gupta AK. Photodynamic therapy for onychomycosis of fingernails. AAD 61st Meeting, San Francisco, 2003. p. 440.
69. Donnely RF, Carron PA, Lightowler JM, Woolfson AD. Bioadhesive patch-based delivery of 5-aminolevulinic acid to the nail for photodynamic therapy of onychomycosis. J Control Release. 2005;103:381-92.